NDA 050638 · Baxter Hlthcare
Penicillin G Potassium In Plastic Container
Penicillin G Potassium · Injection
Last checked: Nov 20, 2026Latest source record: Nov 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Jun 25, 1990
Approved uses
1
Original approval plus efficacy supplements
Registered trials
836
181 Phase 3, 88 recruiting
FAERS reports
2,352
1,747 serious, 241 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 24, 2026.
INDICATIONS AND USAGE Therapy Penicillin G Potassium Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 25, 1990 Original approval · Type 3 - New Dosage Form
3 products under this application
- PENICILLIN G POTASSIUM IN PLASTIC CONTAINER · PENICILLIN G POTASSIUM 60,000 UNITS/ML · INJECTABLE, INJECTION · Prescription
- PENICILLIN G POTASSIUM IN PLASTIC CONTAINER · PENICILLIN G POTASSIUM 20,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued
- PENICILLIN G POTASSIUM IN PLASTIC CONTAINER · PENICILLIN G POTASSIUM 40,000 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Penicillin G" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Evaluation of an Intensive 3-round MDA Strategy Towards Yaws EradicationPivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT03490123 · 56,000 participants · Start Apr 16, 2018 · Primary completion Apr 1, 2020
Drug: R1-Total community treatment with azithromycin; R2-Total community treatment with azithromycin and 3 more · For: Yaws
Sites: Kavieng, Papua New Guinea
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New GuineaPivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT01955252 · 16,000 participants · Start Mar 2013 · Primary completion May 2017
Drug: Azithromycin · For: Yaws
Sites: Londolovit, Papua New Guinea
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisPivotal-lookingRecruiting
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT06184659 · 5,800 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 30, 2028
Drug: Meropenem; Piperacillin/Tazobactam · For: Sepsis; Septic Shock
Sites: Copenhagen, Denmark · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity671
- drug ineffective342
- rash244
- dyspnoea243
- diarrhoea233
- nausea214
- off label use209
- malaise199
- drug intolerance192
- abdominal pain upper180
- cough161
- headache157
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 20 |
| 2006 | 29 |
| 2007 | 57 |
| 2008 | 29 |
| 2009 | 37 |
| 2010 | 28 |
| 2011 | 45 |
| 2012 | 140 |
| 2013 | 29 |
| 2014 | 24 |
| 2015 | 28 |
| 2016 | 40 |
| 2017 | 60 |
| 2018 | 113 |
| 2019 | 141 |
| 2020 | 155 |
| 2021 | 200 |
| 2022 | 296 |
| 2023 | 316 |
| 2024 | 253 |
| 2025 | 196 |
| 2026 | 98 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lyme Neuroborreliosis.
Rauer S, Kastenbauer S, Fingerle V, et al. · Dtsch Arztebl Int 2018 · Systematic Review
- Treatment of syphilis: a systematic review.
Clement ME, Okeke NL, Hicks CB · JAMA 2014 · Systematic Review
- One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis.
Hook EW, Dionne JA, Workowski K, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Equivalence Trial
- Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.
Tuddenham S, Ghanem KG · Clin Infect Dis 2022 · Systematic Review, Research Support, U.S. Gov't, P.H.S.
- Pharmacokinetics and Safety of Intramuscular Injectable Benzathine Penicillin G in Japanese Healthy Participants.
Li Y, Okayama A, Hagi T, et al. · J Clin Pharmacol 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Effectiveness of treating gestational syphilis in the last trimester on the incidence of congenital syphilis: a systematic review and meta-analysis.
Gutiérrez-Tamayo AM, Mirama-Calderón LV, Vallejo-Ortega MT, et al. · Rev Colomb Obstet Ginecol 2025 · Systematic Review, Meta-Analysis
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.